博瑞医药(688166) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue rose by 45.42% to CNY 188,839,905.34 year-on-year[18] - Net profit attributable to shareholders increased by 42.84% to CNY 48,604,937.62 compared to the same period last year[18] - Basic earnings per share increased by 50.00% to CNY 0.12 compared to CNY 0.08 in the same period last year[18] - The company reported a total comprehensive income of approximately ¥48.14 million for Q1 2021, compared to ¥33.97 million in Q1 2020, an increase of 41.6%[55] - Net profit for Q1 2021 reached approximately ¥48.59 million, compared to ¥34.03 million in Q1 2020, representing a growth of 42.9%[55] - The company reported a decrease in total profit to CNY 16,065,986.76 from CNY 25,574,490.39 year-over-year[60] Cash Flow - The net cash flow from operating activities was CNY 3,458,038.02, a significant recovery from a negative cash flow of CNY -4,640,677.09 in the previous year[18] - Cash flow from financing activities resulted in a net inflow of CNY 255,955,908.71, significantly higher than CNY 5,000,000.00 in Q1 2020[66] - The net cash flow from operating activities was negative at RMB -30,296,450.16, worsening from RMB -26,529,151.51 in the same period last year[68] - The company experienced a net increase in cash and cash equivalents of RMB 60,030,741.20, contrasting with a decrease of RMB -74,794,618.28 in Q1 2020[71] Assets and Liabilities - Total assets increased by 16.35% to CNY 2,126,636,828.32 compared to the end of the previous year[18] - Current assets totaled ¥1,283,227,220.30 as of March 31, 2021, compared to ¥1,235,512,188.38 at the end of 2020, indicating a growth of about 3.9%[45] - Non-current assets increased to ¥756,209,120.67 from ¥582,827,117.13, reflecting a growth of approximately 29.7%[45] - Total liabilities amounted to ¥641,917,411.78, up from ¥436,396,262.23, marking an increase of about 47%[47] - Long-term borrowings surged to ¥339,792,456.47 from ¥77,410,000.00, indicating a significant increase of approximately 338%[47] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,099[20] - The largest shareholder, Yuan Jiandong, holds 27.69% of the shares, totaling 113,535,123 shares[20] Research and Development - R&D investment as a percentage of operating revenue decreased by 11.46 percentage points to 11.71%[18] - Research and development expenses for Q1 2021 were approximately ¥12.76 million, down from ¥20.38 million in Q1 2020, indicating a decrease of 37.5%[57] Government Support - The company received government subsidies amounting to CNY 492,308.21 during the reporting period[20] Other Financial Metrics - The weighted average return on equity increased by 0.78 percentage points to 3.34%[18] - The company’s financial expenses showed a significant improvement, with a gain of ¥2,543,741.26 compared to a loss of ¥1,747,139.89 in the previous year[30] - The company incurred a credit impairment loss of CNY -285,176.10, compared to a gain of CNY 195,540.07 in the previous year[60]